Centiva Capital’s Altimmune ALT Stock Holding History

Centiva Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-124,900	Closed	-$483K	–	1064
2025 Q2	$483K	Buy	+124,900	New	+$676K	0.01%	969

Other funds holding ALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Centiva Capital's ALT Position: Q3 2025 in Review

Centiva Capital sold out of Altimmune (ALT) in Q3 2025, closing a stake of 92,319 shares — an estimated $357K sold.

Centiva Capital first reported a position in ALT in Q3 2024 and held it in 3 quarters. The position peaked at $357K in Q2 2025. 158 funds tracked by Wall St. Rank hold ALT as of Q3 2025.

Centiva Capital reported no remaining Altimmune position as of Q3 2025 after selling out during the quarter.
Centiva Capital sold 92,319 Altimmune shares in Q3 2025, an estimated $357K.
Centiva Capital first reported a position in Altimmune in Q3 2024 and held it in 3 quarters.
Centiva Capital's Altimmune position peaked at $357K in Q2 2025.
158 funds tracked by Wall St. Rank held Altimmune as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.